Business Overview
Leveraging its long-standing excellence in legal expertise and deep insight into industry ecosystems, Llinks provides broad and in-depth legal services to enterprises in the healthcare and life sciences sectors. Our services span multiple dimensions, including investment, public listings, intellectual property protection, technology transactions, data compliance, and regulatory matters, enabling us to deliver integrated, high-value solutions that comprehensively address clients’ complex business objectives. Our team brings together professionals with diverse backgrounds in pharmaceuticals and healthcare, offering solid research foundations and extensive practical experience on key issues such as compliance operations for life sciences enterprises, professional practice standards, advertising and promotion, health data governance, compliant use of medical insurance funds, the integration of medical care and elder care models, and their legal boundaries. In addition, we have a deep understanding of the business models and commercial needs of life sciences companies, ensuring that our strategies in capital markets, intellectual property, technology transactions, and compliance system development are closely aligned with clients’ real-world requirements.
Llinks has already provided legal services to numerous institutions in the healthcare and life sciences sectors. Our clients include industry leaders and established large enterprises, as well as innovative entities in rapid growth or early start-up stages. The specific industry segments we serve cover pharmaceutical and medical device companies, healthcare institutions, drug regulatory authorities, disease prevention and control agencies, as well as organizations engaged in the research, development, production, distribution, and sales of pharmaceuticals and medical devices, along with investment funds dedicated to the healthcare and life sciences industries.
Practice Highlights
-
Represented Chipscreen Biosciences in reaching a chidamide licensing and distribution agreement with Nizhpharm
-
Represented StairMed in completing a RMB 500 million strategic financing
-
Represented Escugen Biotechnology in its global licensing transaction
-
Represented United Imaging Intelligence in completing a RMB 1 billion Series A financing
-
Represented Allist Pharmaceuticals in obtaining Greater China rights to KRAS G12C and SHP2 inhibitors
-
Represented United Imaging Healthcare in raising over RMB 10 billion and its successful listing on the STAR Market of the Shanghai Stock Exchange